ES3056791T3 - Omega-3 fatty acid, homocystein and vitamin d levels to identify and attenuate cognitive aging in individuals - Google Patents

Omega-3 fatty acid, homocystein and vitamin d levels to identify and attenuate cognitive aging in individuals

Info

Publication number
ES3056791T3
ES3056791T3 ES18714287T ES18714287T ES3056791T3 ES 3056791 T3 ES3056791 T3 ES 3056791T3 ES 18714287 T ES18714287 T ES 18714287T ES 18714287 T ES18714287 T ES 18714287T ES 3056791 T3 ES3056791 T3 ES 3056791T3
Authority
ES
Spain
Prior art keywords
vitamin
subject
omega
fatty acid
cognitive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18714287T
Other languages
English (en)
Spanish (es)
Inventor
Gene Bowman
Julie Hudry-Labbe
Jeroen Antonius Johannes Schmitt
Corina Boschat
Claus Rieker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2017/074731 external-priority patent/WO2018060396A1/en
Priority claimed from EP17193916.8A external-priority patent/EP3388061A1/en
Priority claimed from PCT/EP2017/082148 external-priority patent/WO2018188771A1/en
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Application granted granted Critical
Publication of ES3056791T3 publication Critical patent/ES3056791T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
ES18714287T 2017-04-11 2018-04-05 Omega-3 fatty acid, homocystein and vitamin d levels to identify and attenuate cognitive aging in individuals Active ES3056791T3 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762484156P 2017-04-11 2017-04-11
US201762484119P 2017-04-11 2017-04-11
PCT/EP2017/074731 WO2018060396A1 (en) 2016-09-29 2017-09-29 Omega 3 fatty acids and choline as neuroprotectant in patients with no dementia
EP17193916.8A EP3388061A1 (en) 2017-04-11 2017-09-29 Omega 3 fatty acids, no releasing compound, vitamin b12 and choline as neuroprotectant in patients with no dementia
US201762580574P 2017-11-02 2017-11-02
PCT/EP2017/082148 WO2018188771A1 (en) 2017-04-11 2017-12-11 Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals
PCT/EP2018/058701 WO2018189020A2 (en) 2017-04-11 2018-04-05 Methods for identifying pre-disposition to cognitive decline and agents for reducing or preventing cognitive decline, or improving cognitive ability

Publications (1)

Publication Number Publication Date
ES3056791T3 true ES3056791T3 (en) 2026-02-24

Family

ID=67682482

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18714287T Active ES3056791T3 (en) 2017-04-11 2018-04-05 Omega-3 fatty acid, homocystein and vitamin d levels to identify and attenuate cognitive aging in individuals

Country Status (9)

Country Link
US (6) US20210128587A1 (https=)
EP (3) EP3609490A1 (https=)
JP (6) JP7270546B2 (https=)
CN (3) CN110381935A (https=)
AU (5) AU2017408873A1 (https=)
BR (3) BR112019017949A2 (https=)
CA (3) CA3054846A1 (https=)
ES (1) ES3056791T3 (https=)
MX (2) MX2019010484A (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019017949A2 (pt) * 2017-04-11 2020-05-19 Nestle Sa níveis de ácidos graxos ômega-3 e vitamina d para identificar e atenuar o envelhecimento cognitivo em indivíduos
WO2018188771A1 (en) 2017-04-11 2018-10-18 Nestec S.A. Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals
CN113252806B (zh) * 2021-03-25 2023-08-29 嘉兴学院 S-腺苷同型半胱氨酸在制备用于诊断或治疗川崎病的产品中的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
GB0016460D0 (en) * 2000-07-04 2000-08-23 Axis Shield Asa Assay
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US8017657B1 (en) * 2001-09-07 2011-09-13 Advanced Medical Instruments Composition for the treatment and prevention of endothelial dysfunction
EP1604671A4 (en) * 2003-02-26 2006-03-29 Kyowa Hakko Kogyo Kk MUSCLE TREATMENT AND MEANS FOR PREVENTING OR TREATING MUSCLE WEAKNESS
US20070078114A1 (en) * 2005-09-02 2007-04-05 Myriad Genetics, Incorporated Combination therapy for alzheimer's disease and other diseases
US20080003330A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Infant formulas for early brain development
ES2808406T3 (es) 2007-06-26 2021-02-26 Nutricia Nv Mejora de la memoria en sujetos con un mini examen del estado mental de 24-26
WO2009002148A1 (en) * 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
US20100292330A1 (en) * 2007-10-04 2010-11-18 Yuanlong Pan Compositions and methods for enhancing cognitive function
EP2224930B1 (en) * 2008-01-04 2016-06-15 Nestec S.A. Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing congnitive and related functions
EP2373999A4 (en) 2008-12-09 2012-11-07 Stephanie Fryar-Williams NEW BIOMARKERS
US8933255B2 (en) * 2008-12-31 2015-01-13 Nitromega Corp. Nutraceuticals containing nitro fatty acids
CN101897706A (zh) * 2009-05-27 2010-12-01 北京奥萨医药研究中心有限公司 含有叶酸和b族维生素的组合物及其用途
WO2010143053A1 (en) * 2009-06-10 2010-12-16 Energy4Life Ag Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders
EP2568826A4 (en) * 2010-05-13 2014-03-26 Nitromega Corp NITRATED FATTY ACIDS, NEUROPROTECTION AND / OR INHIBITION OF COGNITIVE DECLINE
EP2627326A2 (en) 2010-10-12 2013-08-21 Vifor SA Novel omega-3 and omega-6 fatty acid compositions and uses thereof
ES2727043T3 (es) * 2011-03-18 2019-10-11 Nestle Sa Composiciones y métodos útiles para mejorar enfermedades relacionadas con la edad
RU2014121888A (ru) * 2011-10-31 2015-12-10 Н.В. Нютрисиа Композиция для улучшения оценки батареи нейропсихологических тестов
BR112015002309A2 (pt) * 2012-08-07 2017-07-04 Buck Inst Res Aging formulação de múltiplos componentes para aprimorar a função neurológica
FR3002044A1 (fr) * 2013-02-08 2014-08-15 Centre Nat Rech Scient Marqueur dyrk1a pour la maladie d'alzheimer
WO2014151364A1 (en) 2013-03-15 2014-09-25 Buck Institute For Research On Aging Improved cognitive supplements
US20140271844A1 (en) * 2013-03-15 2014-09-18 Nitromega Corp. Compositions containing nitro fatty acids
EP2899543A1 (en) 2014-01-28 2015-07-29 Predemtec GmbH Biomarker and methods for early diagnosis of Alzheimer's disease
GB201405033D0 (en) * 2014-03-20 2014-05-07 Isis Innovation Combination therapy
EP3310349B1 (en) * 2015-06-22 2021-01-13 Société des Produits Nestlé S.A. Compositions and methods for enhancing neurogenesis in animals
WO2017004436A2 (en) * 2015-07-01 2017-01-05 The Regents Of The University Of California A therapeutic system comprising pharmaceuticals in combination with metabolic enhancement for neurodegeneration
WO2017053773A1 (en) * 2015-09-25 2017-03-30 Buck Institute For Research On Aging Compositions and methods for specific biological cognitive functions in neurodegenerative diseases
EP3463321A1 (en) * 2016-05-27 2019-04-10 Nestec S.A. Nutritional composition for treating or preventing impaired mobility
MX385552B (es) * 2016-09-29 2025-03-18 Soc Des Produits Nestle S A Star Ácidos grasos omega 3, compuesto que libera no y vitamina b12 como neuroprotector en pacientes sin demencia.
BR112019017949A2 (pt) * 2017-04-11 2020-05-19 Nestle Sa níveis de ácidos graxos ômega-3 e vitamina d para identificar e atenuar o envelhecimento cognitivo em indivíduos

Also Published As

Publication number Publication date
JP7270547B2 (ja) 2023-05-10
AU2017408873A1 (en) 2019-08-29
MX2019010828A (es) 2019-10-15
US20230310488A1 (en) 2023-10-05
CA3054864A1 (en) 2018-10-18
BR112019017949A2 (pt) 2020-05-19
EP3609491A2 (en) 2020-02-19
JP7434459B2 (ja) 2024-02-20
AU2024200882B9 (en) 2025-11-20
US20210263048A1 (en) 2021-08-26
CN110381935A (zh) 2019-10-25
CA3054869A1 (en) 2018-10-18
EP3609490A1 (en) 2020-02-19
JP2022172152A (ja) 2022-11-15
AU2024200882A1 (en) 2024-02-29
AU2018251092A1 (en) 2019-09-05
BR112019018729A2 (pt) 2020-04-07
AU2018251094A1 (en) 2019-09-05
EP3609491B1 (en) 2025-11-05
BR112019020008A2 (pt) 2020-04-28
EP3609487A1 (en) 2020-02-19
JP2020516864A (ja) 2020-06-11
AU2018251094B2 (en) 2023-11-02
US20210128587A1 (en) 2021-05-06
CA3054846A1 (en) 2018-10-18
MX2019010484A (es) 2019-10-17
JP2023030130A (ja) 2023-03-07
EP3609487B1 (en) 2026-03-18
US20230028607A1 (en) 2023-01-26
US20240041915A1 (en) 2024-02-08
JP7434458B2 (ja) 2024-02-20
JP2022166175A (ja) 2022-11-01
JP2020516586A (ja) 2020-06-11
JP7270546B2 (ja) 2023-05-10
JP7524294B2 (ja) 2024-07-29
AU2018251092B2 (en) 2024-02-29
CN110430873A (zh) 2019-11-08
CN110475553A (zh) 2019-11-19
AU2024200882B2 (en) 2025-07-24
JP2020516862A (ja) 2020-06-11
US20200054665A1 (en) 2020-02-20
AU2025220690A1 (en) 2025-09-04

Similar Documents

Publication Publication Date Title
Ranjbar et al. Effects of zinc supplementation in patients with major depression: a randomized clinical trial
AU2024200882B9 (en) Omega-3 fatty acid, homocystein and vitamin D levels to identify and attenuate cognitive aging in individuals
AU2017336291B2 (en) Omega 3 fatty acids, no releasing compound and vitamin B12 as neuroprotectant in patients with no dementia
Ruusunen Diet and depression: an epidemiological study
Sánchez et al. Simplified dietary acute tryptophan depletion: effects of a novel amino acid mixture on the neurochemistry of C57BL/6J mice
US12576102B2 (en) Methods for identifying pre-disposition to cognitive decline and agents for reducing or preventing cognitive decline, or improving cognitive ability
Yi et al. A randomized, placebo-controlled, double-blind trial of supplemental docosahexaenoic acid on cognitive processing speed and executive function in females of reproductive age with phenylketonuria: A pilot study
EP3388061A1 (en) Omega 3 fatty acids, no releasing compound, vitamin b12 and choline as neuroprotectant in patients with no dementia
CA3034187C (en) Omega 3 fatty acids and choline as neuroprotectant in patients with no dementia
Sakamoto et al. Protein Quality Not Excellent and Essential Fatty Acid Deficiency in Evacuation Shelter Food Analysis in the Noto Peninsula Earthquake: Comparison with the 2024 Simultaneous National Survey in Japan
Martínez-Noguera et al. Short-Term Methylcobalamin Supplementation Is Associated with Changes in Anaerobic and Cognitive Performance in Amateur Cyclists: A Randomized Crossover Trial
Lindberg Blood and Brain Metabolic Signatures of Depression, Schizophrenia, and Alcohol Use Disorder
Pusparini Decreased serum homocysteine levels after micronutrient supplementation in older people
Rosenberg Aging, B vitamins and cognitive decline
Kristiansson Central inflammatory markers correlate with personality traits and increase in response to surgical stress